06.02.16
Genmab has achieved $30 million milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech, triggered by the first commercial sale of the drug in Europe.
The European Commission recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX as monotherapy for the treatment of relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression.
"We continue to be impressed by the rapid speed with which our collaboration partner, Janssen, has been able to develop and launch DARZALEX in Europe," said Jan van de Winkel, Ph.D., chief executive officer of Genmab.
The European Commission recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX as monotherapy for the treatment of relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression.
"We continue to be impressed by the rapid speed with which our collaboration partner, Janssen, has been able to develop and launch DARZALEX in Europe," said Jan van de Winkel, Ph.D., chief executive officer of Genmab.
